367 related articles for article (PubMed ID: 24882262)
21. The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients.
Morra E; Lazzarino M; Brusamolino E; Pagnucco G; Castagnola C; Bernasconi P; Orlandi E; Corso A; Santagostino A; Bernasconi C
Cancer; 1993 Jul; 72(2):439-45. PubMed ID: 8319175
[TBL] [Abstract][Full Text] [Related]
22. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases.
Sancho JM; Ribera JM; Romero MJ; Martín-Reina V; Giraldo P; Ruiz E
Haematologica; 2006 Mar; 91(3):ECR02. PubMed ID: 16533729
[TBL] [Abstract][Full Text] [Related]
23. Flow cytometric detection of liposomal cytarabine in cerebrospinal fluid of patients treated with intrathecal chemotherapy.
Stacchini A; Demurtas A; Aliberti S
Cytometry B Clin Cytom; 2012 Sep; 82(5):280-2. PubMed ID: 22539249
[TBL] [Abstract][Full Text] [Related]
24. Hypofractionated moderate dose radiation, intrathecal chemotherapy, and repetitive reinduction/reconsolidation systemic therapy for central nervous system relapse of acute lymphoblastic leukemia in children.
Belasco JB; Goldwein JW; Simms S; Griffin G; D'Angio G; Lange B
Med Pediatr Oncol; 2000 Feb; 34(2):125-31. PubMed ID: 10657874
[TBL] [Abstract][Full Text] [Related]
25. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.
Matloub Y; Lindemulder S; Gaynon PS; Sather H; La M; Broxson E; Yanofsky R; Hutchinson R; Heerema NA; Nachman J; Blake M; Wells LM; Sorrell AD; Masterson M; Kelleher JF; Stork LC;
Blood; 2006 Aug; 108(4):1165-73. PubMed ID: 16609069
[TBL] [Abstract][Full Text] [Related]
26. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
27. Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16.
Jeha S; Pei D; Choi J; Cheng C; Sandlund JT; Coustan-Smith E; Campana D; Inaba H; Rubnitz JE; Ribeiro RC; Gruber TA; Raimondi SC; Khan RB; Yang JJ; Mullighan CG; Downing JR; Evans WE; Relling MV; Pui CH
J Clin Oncol; 2019 Dec; 37(35):3377-3391. PubMed ID: 31657981
[TBL] [Abstract][Full Text] [Related]
28. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
Nachman J; Sather HN; Cherlow JM; Sensel MG; Gaynon PS; Lukens JN; Wolff L; Trigg ME
J Clin Oncol; 1998 Mar; 16(3):920-30. PubMed ID: 9508174
[TBL] [Abstract][Full Text] [Related]
29. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
Aichberger KJ; Herndlhofer S; Agis H; Sperr WR; Esterbauer H; Rabitsch W; Knöbl P; Haas OA; Thalhammer R; Schwarzinger I; Sillaber C; Jäger U; Valent P
Eur J Clin Invest; 2007 Oct; 37(10):808-13. PubMed ID: 17727673
[TBL] [Abstract][Full Text] [Related]
30. Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation.
Hilgendorf I; Wolff D; Junghanss C; Kahl C; Leithaeuser M; Steiner B; Casper J; Freund M
Ann Hematol; 2008 Dec; 87(12):1009-12. PubMed ID: 18704421
[TBL] [Abstract][Full Text] [Related]
31. An intensive re-treatment protocol for children with an isolated CNS relapse of acute lymphoblastic leukemia.
Ribeiro RC; Rivera GK; Hudson M; Mulhern RK; Hancock ML; Kun L; Mahmoud H; Sandlund JT; Crist WM; Pui CH
J Clin Oncol; 1995 Feb; 13(2):333-8. PubMed ID: 7844594
[TBL] [Abstract][Full Text] [Related]
32. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Xie XT; Jiang SY; Li BS; Yang LL
Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
[TBL] [Abstract][Full Text] [Related]
33. Treatment of CNS relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study.
Winick NJ; Smith SD; Shuster J; Lauer S; Wharam MD; Land V; Buchanan G; Rivera G
J Clin Oncol; 1993 Feb; 11(2):271-8. PubMed ID: 8426204
[TBL] [Abstract][Full Text] [Related]
34. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
Benesch M; Siegler N; Hoff Kv; Lassay L; Kropshofer G; Müller H; Sommer C; Rutkowski S; Fleischhack G; Urban C
Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818
[TBL] [Abstract][Full Text] [Related]
35. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M
Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345
[TBL] [Abstract][Full Text] [Related]
36. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Ferreri AJ; Reni M; Foppoli M; Martelli M; Pangalis GA; Frezzato M; Cabras MG; Fabbri A; Corazzelli G; Ilariucci F; Rossi G; Soffietti R; Stelitano C; Vallisa D; Zaja F; Zoppegno L; Aondio GM; Avvisati G; Balzarotti M; Brandes AA; Fajardo J; Gomez H; Guarini A; Pinotti G; Rigacci L; Uhlmann C; Picozzi P; Vezzulli P; Ponzoni M; Zucca E; Caligaris-Cappio F; Cavalli F;
Lancet; 2009 Oct; 374(9700):1512-20. PubMed ID: 19767089
[TBL] [Abstract][Full Text] [Related]
37. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
Doorduijn JK; van Imhoff GW; van der Holt B; Schouten HC; Schaafsma MR; MacKenzie MA; Baars JW; Kersten MJ; Lugtenburg PJ; van den Bent MJ; Enting RH; Spoelstra FM; Poortmans P; Bromberg JEC
Hematol Oncol; 2017 Dec; 35(4):497-503. PubMed ID: 27530779
[TBL] [Abstract][Full Text] [Related]
38. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis.
Sancho JM; Ribera JM; Oriol A; Hernandez-Rivas JM; Rivas C; Bethencourt C; Parody R; Deben G; Bello JL; Feliu E;
Cancer; 2006 Jun; 106(12):2540-6. PubMed ID: 16700036
[TBL] [Abstract][Full Text] [Related]
39. Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma.
Segot A; Raffoux E; Lengline E; Thieblemont C; Dombret H; Boissel N; Cluzeau T
Ann Hematol; 2015 Nov; 94(11):1859-63. PubMed ID: 26280395
[TBL] [Abstract][Full Text] [Related]
40. Intrathecal liposomal cytarabine in relapsed or refractory infant and pediatric leukemias: the Children's Hospital of Philadelphia experience and review of the literature.
Seif AE; Reilly AF; Rheingold SR
J Pediatr Hematol Oncol; 2010 Nov; 32(8):e349-52. PubMed ID: 20962675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]